On April, 4 WallStreet awaited Mustang Bio, Inc. (NASDAQ:MBIO)’s earnings release, as reported by Faxor. The EPS diference is $0.05 or 22.73 % down from last years number. Previous year: $-0.22; Analysts forcast: $-0.27. Analysts at Wall Street see Mustang Bio, Inc.’s -3.57 % EPS growth compared to $-0.28 EPS for previous quarter. The stock decreased 9.38% or $0.38 during the last trading session, hitting $3.67.Currently Mustang Bio, Inc. is downtrending after 64.63% change in last March 6, 2018. MBIO has also 51,884 shares volume. MBIO underperformed by 69.00% the S&P500.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology.The company has $99.21 million market cap. The Company’s lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials.Last it reported negative earnings. Mustang Bio, Inc. has a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer; and a license agreement with Harvard University.

For more Mustang Bio, Inc. (NASDAQ:MBIO) news released briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights – GlobeNewswire” released on November 13, 2018, “Mustang Bio to Present at Biotech Innovations Conference – GlobeNewswire” on April 04, 2018, “Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes – GlobeNewswire” with a publish date: June 25, 2018, “Mustang Bio: What The Latest Development For MB-102 Entails – Seeking Alpha” and the last “Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights – GlobeNewswire” with publication date: March 29, 2018.